Oct 10, 2024 · PRAME (preferentially expressed antigen in melanoma) is a cancer testis antigen expressed by melanoma and other malignant neoplasms with expression in normal tissue largely …

PRAME (preferentially expressed antigen of melanoma) is a protein that in humans is encoded by the PRAME gene. [3][4][5] Five alternatively spliced transcript variants encoding the same protein have …

PRAME stands for “preferentially expressed antigen in melanoma.” It is a special type of protein called a cancer-testis antigen. This means that PRAME is usually found in cancer cells and normal cells …

In this study we examined the immunohistochemical expression of PRAME in 400 melanocytic tumors, including 155 primary and 100 metastatic melanomas, and 145 melanocytic nevi.

Aug 2, 2025 · PRAME, or “Preferentially expressed Antigen in Melanoma,” is a protein found on cancer cells that can be recognized by the immune system.

Jul 16, 2024 · PRAME emerges as a promising biomarker and therapeutic target in malignant melanoma, offering avenues for improved diagnosis, prognostication, and treatment. Its pivotal roles …

Feb 12, 2024 · As investigators continue to refine and carve out a role for targeted therapies in the treatment paradigm across tumor types, preferentially expressed antigen in melanoma (PRAME) has …

Mar 26, 2024 · Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML …

12 hours ago · Shares of MiNK Therapeutics Inc. (INKT) are up by 73% in the pre-market following the announcement of a strategic collaboration with C-Further, an international pediatric oncology …

PRAME has the potential to serve as a prognostic pan-cancer biomarker and is correlated with tumor immunity. Its use may help shed light on optimum cancer therapies. With changes to people’s living …